Sign In
Buy CPIX
$5.77
+0.0700 (+1.23%)
At Close: Jun 02, 2026
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q3 2025 FINANCIAL RESULTS & COMPANY UPDATE
04:05pm, Tuesday, 28'th Oct 2025
NASHVILLE, Tenn. , Oct. 28, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its third quarter 2025 financi
CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO
09:05am, Monday, 20'th Oct 2025
Cumberland to expand its gastroenterology offerings with the market-leading Helicobacter pylori therapy NASHVILLE, Tenn. , Oct. 20, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX)
RedHill's Talicia® Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership Deal
09:00am, Monday, 20'th Oct 2025
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) invests $4 million in exchange for a 30% ownership stake and joint control in RedHill's Talicia business U.S. co-commercialization partnership designed t
CUMBERLAND PHARMACEUTICALS' VIBATIV® ADDED TO NATIONAL GROUP PURCHASING AGREEMENT WITH PREMIER, INC.
09:05am, Monday, 13'th Oct 2025
Premier Membership includes 4,350 U.S. Hospitals NASHVILLE, Tenn. , Oct. 13, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, has added their po
CUMBERLAND PHARMACEUTICALS ANNOUNCES PRODUCT APPROVAL IN MEXICO
09:05am, Wednesday, 01'st Oct 2025
Injectable Ibuprofen Approved for Treating Pain & Fever NASHVILLE, Tenn. , Oct. 1 , 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today annou
TABUK LAUNCHES VIBATIV® FDA-APPROVED ANTIBIOTIC WITH LIFE-SAVING POTENTIAL IN SAUDI ARABIA
09:05am, Monday, 29'th Sep 2025
Vibativ ® treats patients with pneumonia and serious skin infections NASHVILLE, Tenn. and RIYADH, Saudi Arabia , Sept.
Cumberland Pharmaceuticals Inc. (CPIX) Q2 2025 Earnings Call Transcript
01:52am, Wednesday, 06'th Aug 2025
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants A. J. Kazimi - Founder, Chairman, President & CEO John Michael Hamm - VP
Cumberland Pharmaceuticals Reports 23% Revenue Growth Year-to-Date
04:05pm, Tuesday, 05'th Aug 2025
NASHVILLE, Tenn. , Aug. 5, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands de
CUMBERLAND PHARMACEUTICALS RECEIVES VIZIENT CONTRACT FOR NEW VIBATIV® 4-VIAL STARTER PAK
09:05am, Monday, 04'th Aug 2025
Vizient serves more than 65% of the nation's acute care providers, including 97% of academic medical centers NASHVILLE, Tenn. , Aug. 4, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CP
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q2 2025 FINANCIAL RESULTS & COMPANY UPDATE
04:05pm, Tuesday, 29'th Jul 2025
NASHVILLE, Tenn. , July 29, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its second quarter 2025 finan
Cumberland Pharmaceuticals Shares Phase 2 FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference
09:05am, Monday, 23'rd Jun 2025
New pharmacokinetic and cardiac biomarker data further demonstrate ifetroban's potential to protect the heart and reduce cardiac damage in DMD patients NASHVILLE, Tenn. , June 23, 2025 /PRNewswire/ --
NEW STUDY FINDS CALDOLOR® SAFE AND EFFECTIVE FOR OPIOID-SPARING PAIN MANAGEMENT IN OLDER ADULTS
04:05pm, Tuesday, 27'th May 2025
Analysis Shows 23% Reduction in Morphine Use with Favorable Safety Profile in Patients 60 Years of Age and Older NASHVILLE, Tenn. , May 27, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq
CUMBERLAND PHARMACEUTICALS PARTNERS WITH QUREIGHT TO ADVANCE INNOVATIVE IDIOPATHIC PULMONARY FIBROSIS TREATMENT RESEARCH
04:05pm, Tuesday, 13'th May 2025
Cumberland leveraging Qureight's deep-learning AI platform for its Phase II FIGHTING FIBROSIS™ clinical trial NASHVILLE, Tenn. and CAMBRIDGE, England , May 13, 2025 /PRNewswire/ -- Cumberland Phar
Cumberland Pharmaceuticals, Inc. (CPIX) Q1 2025 Earnings Call Transcript
04:23am, Saturday, 10'th May 2025
Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX ) Q1 2025 Earnings Conference Call May 6, 2024 4:30 PM ET Company Participants Molly Aggas - Account Supervisor, Dalton Agency A.J. Kazimi - CEO Todd Anth
Cumberland Pharmaceuticals Reports 38% Revenue Growth in Q1 2025
04:05pm, Tuesday, 06'th May 2025
NASHVILLE, Tenn. , May 6, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands del
